ArticleThoracic cancer2021

Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Eun Hee Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.